AbbVie’s (ABBV) Rinvoq Gets FDA Nod for Atopic Dermatitis

Posted byZacks Equity Research Leave a comment on AbbVie’s (ABBV) Rinvoq Gets FDA Nod for Atopic Dermatitis

FDA approves AbbVie’s (ABBV) Rinvoq for the treatment of moderate to severe atopic dermatitis in adults and children aged 12 and above. This is the third indication for Rinvoq in…

Leave a comment

Your email address will not be published. Required fields are marked *